Reflux, Properly Explained: From Heartburn to Barrett's, and Every Treatment Between Diet and Surgery

Reflux is one of the most common complaints in gastroenterology and, quietly, one of the most misunderstood. Most people assume reflux means heartburn, heartburn means acid, and acid means a proton pump inhibitor. The reality is more interesting. Reflux sits on a wide spectrum — from mild occasional heartburn through to severe oesophagitis, Barrett's oesophagus, and in a small number of patients, oesophageal adenocarcinoma. Some reflux is acid; some is bile; some is weakly acidic or non-acid and therefore invisible to a traditional acid test. Some patients have reflux driven primarily by a failing lower oesophageal sphincter; others by oesophageal dysmotility or delayed gastric emptying; and a few have reflux made worse, not better, by long-term acid suppression. This article walks through the full spectrum: what reflux actually is, how severity is graded, what Barrett's oesophagus means and what to do about it, how modern testing pins down the cause, and the full treatment ladder from simple diet and lifestyle through to anti-reflux surgery.

What Reflux Actually Is, Anatomically

The oesophagus is protected from the stomach by a combined valve system: the intrinsic lower oesophageal sphincter, the extrinsic crural diaphragm, and the angle of His where the oesophagus meets the stomach. When this valve complex is working, the oesophagus remains alkaline, smooth muscle coordination clears any small amount of reflux within seconds, and saliva neutralises the rest. When the valve becomes incompetent — from a hiatus hernia, from transient lower oesophageal sphincter relaxations, or from reduced crural tone — gastric contents are allowed to reach the oesophagus for longer than they should. If those contents are acidic, the patient feels burning. If they are bile-rich or weakly acidic, the patient may feel regurgitation, fullness, cough, hoarseness, or sometimes nothing at all, despite real tissue damage. Reflux, in other words, is a mechanical and physiological problem first and an acid problem second.

The reflux spectrum: anatomy of the antireflux barrier, Los Angeles severity grades A–D, and the Barrett's progression from metaplasia to cancer.

Grading Severity: From Occasional Heartburn to Erosive Disease

Reflux severity is assessed across three dimensions: symptoms, mucosal damage, and complications. Symptomatic severity is captured by frequency and intensity — mild reflux is occasional and easily ignored; severe reflux interferes with sleep, diet, or work. Mucosal severity is graded endoscopically using the Los Angeles classification: Grade A is one or more small mucosal breaks of 5 mm or less, Grade B shows mucosal breaks greater than 5 mm, Grade C has breaks that extend between the tops of two or more folds, and Grade D is a circumferential break involving at least 75% of the circumference. Non-erosive reflux disease — typical symptoms with a normal-looking oesophagus — is surprisingly common and requires functional testing rather than endoscopy to characterise. Complications move the patient into a separate tier: peptic stricture, Barrett's oesophagus, aspiration, and oesophageal adenocarcinoma each change management and urgency.

Barrett's Oesophagus: What It Is and What It Means

Barrett's oesophagus is a metaplastic change in which the normal squamous lining of the lower oesophagus is replaced by intestinal-type columnar epithelium, usually in response to long-standing reflux. It looks like salmon-pink tongues extending up from the gastro-oesophageal junction and is confirmed by biopsy showing specialised intestinal metaplasia with goblet cells. Barrett's matters because it is the only established precursor to oesophageal adenocarcinoma, the fastest-rising solid cancer in the Western world over the past four decades. The absolute annual cancer risk in non-dysplastic Barrett's is low — around 0.2 to 0.5 per cent per year — but it is not zero, and the risk escalates substantially once dysplasia develops. Low-grade dysplasia raises the annual risk to around 0.7 per cent; high-grade dysplasia raises it to 7 per cent or higher. Recognising and then carefully surveilling Barrett's is one of the clearest examples in gastroenterology of a screening intervention that saves lives.

Barrett's Surveillance: Who, How Often, and Why

Surveillance endoscopy in Barrett's aims to detect dysplasia early so that endoscopic therapy can prevent cancer. For non-dysplastic Barrett's less than 3 cm long, surveillance every three to five years is usually appropriate. Longer segments (3 cm or more) shorten the interval to every three years. Indefinite for dysplasia on biopsy warrants repeat endoscopy within six months on an optimised PPI regimen. Confirmed low-grade dysplasia merits endoscopic eradication therapy in most contemporary guidelines — typically radiofrequency ablation — rather than watch-and-wait surveillance, because progression rates and cancer risk are high enough to justify intervention. High-grade dysplasia and intramucosal cancer are almost always treated endoscopically: visible lesions are removed by endoscopic mucosal resection or endoscopic submucosal dissection, and the remaining Barrett's segment is ablated. Modern endoscopic therapy cures most high-grade dysplasia and early cancer without the need for oesophagectomy, which was the standard of care only a generation ago.

Barrett's is not a disease to fear; it is a diagnosis to respect. Detected early and surveilled properly, it is one of the most preventable cancers in gastroenterology. Ignored, it becomes one of the deadliest.

Non-Acid Reflux, Bile Reflux, and the Low-Acid Paradox

Not all reflux is acid, and this is where clinical practice often runs aground. Weakly acidic and non-acidic reflux occurs when refluxate has a pH above 4 but still distends and irritates the oesophagus. Bile reflux, or duodenogastro-oesophageal reflux, involves bile salts and pancreatic enzymes travelling retrograde from the duodenum through the stomach into the oesophagus, and it is particularly common in patients who have had gastric surgery, cholecystectomy, or significant motility impairment. Bile reflux causes burning, regurgitation, and a characteristic bitter taste, damages mucosa by a different mechanism than acid, and does not respond to acid suppression alone. The low-acid paradox is the observation that some patients with reduced gastric acid production — from chronic atrophic gastritis, long-term high-dose PPI, or previous H. pylori — can still have symptomatic reflux because volume and pressure matter as much as pH. Recognising the non-acid and bile components of reflux is essential before escalating acid suppression indefinitely.

Motility Disorders That Masquerade as Reflux

A significant minority of patients labelled as "refractory reflux" in fact have a motility disorder. Achalasia, in which the lower oesophageal sphincter fails to relax, presents with regurgitation of undigested food and is frequently mistaken for reflux early in its course. Ineffective oesophageal motility and absent contractility produce poor clearance of refluxed material and worsen symptoms even when the acid component is modest. Delayed gastric emptying, or gastroparesis, increases intragastric volume and pressure and promotes reflux mechanically. Rumination syndrome, in which an involuntary abdominal contraction returns recently swallowed food to the mouth, looks exactly like reflux to the untrained ear but responds to behavioural therapy, not PPIs. Distinguishing these conditions from typical reflux requires functional testing — in particular, high-resolution manometry, and occasionally scintigraphy for emptying and reflux.

The diagnostic toolkit and treatment ladder: what each test is looking for, and how treatment escalates from simple lifestyle changes to anti-reflux surgery.

The Diagnostic Toolkit: What Each Test Is Actually Looking For

Gastroscopy is the starting point for most patients with persistent reflux, alarm symptoms, or a suspicion of Barrett's. It evaluates the mucosa, grades oesophagitis, identifies hiatus hernia, and allows biopsy. But a normal gastroscopy does not exclude reflux — up to 70% of reflux is non-erosive on appearance. A 24-hour oesophageal pH study measures acid exposure time at a catheter 5 cm above the lower sphincter, and a pH-impedance study additionally captures non-acidic and weakly acidic reflux events, associating each with symptom episodes to calculate a symptom association probability. High-resolution manometry maps the pressure and coordination of peristalsis and of the lower sphincter, identifying achalasia, ineffective motility, and hypercontractile disorders. Reflux scintigraphy uses a radiolabelled meal to visualise gastric emptying and proximal reflux of content, and is particularly useful when bile reflux, rumination, or gastroparesis are suspected. Each test answers a different question, and the common error is ordering the wrong test for the clinical question. A precise diagnosis determines the right treatment; empirical escalation on the wrong diagnosis is how refractory reflux gets made.

Treatment Step One: Diet, Lifestyle, and the Things That Actually Matter

Lifestyle changes are often dismissed as token advice, but in the right patient they are genuinely effective. Weight loss reduces intragastric pressure and transient relaxations of the lower sphincter and is the single highest-impact lifestyle intervention. Elevating the head of the bed by 15–20 cm and avoiding food for at least three hours before lying down dramatically reduces nocturnal reflux exposure. Smoking and alcohol both lower sphincter pressure and should be addressed. Specific food triggers vary between patients, but fatty meals, chocolate, peppermint, carbonated drinks, and large portion sizes are the most consistent culprits. None of these are glamorous, but taken together they can shift a patient from PPI-dependent to PPI-optional — which is often the goal that matters.

Treatment Step Two: Acid Suppression, and When to Upgrade

Proton pump inhibitors remain the cornerstone of reflux pharmacotherapy. Taken thirty to sixty minutes before the first meal of the day, a standard-dose PPI heals the majority of erosive oesophagitis and controls symptoms in most patients. When standard dosing is insufficient, splitting the dose to twice daily before breakfast and before dinner captures both acid production peaks. Patients with CYP2C19 fast-metaboliser genotypes often underperform on PPIs — a pharmacological reality that has been recognised only relatively recently. For these patients, and for those with severe oesophagitis, nocturnal breakthrough, or persistent symptoms despite twice-daily PPI, vonoprazan — a potassium-competitive acid blocker — offers faster, stronger, and more consistent acid suppression that is unaffected by CYP2C19 status. Vonoprazan is not a replacement for PPI in every patient, but for refractory erosive disease it is a meaningful upgrade, and its use in reflux is expanding rapidly.

Treatment Step Three: Motility, Neuromodulation, and Bile

When acid suppression alone is not enough, the additional tools fall into three groups. Prokinetics — most commonly metoclopramide or domperidone — accelerate gastric emptying and lower sphincter tone and are useful when delayed emptying is contributing to reflux; their long-term use requires attention to neurological side effects. Neuromodulators, particularly low-dose tricyclics such as amitriptyline (Endep) 10–25 mg nocte, reduce oesophageal hypersensitivity and address the central component of reflux symptoms that persist despite normal acid exposure — the "functional heartburn" overlap that PPIs alone never touch. For bile reflux, treatment shifts to bile acid binders such as cholestyramine, sucralfate to coat and protect mucosa, and in selected cases ursodeoxycholic acid to alter bile composition. Patients with confirmed bile reflux who fail medical therapy may be candidates for anti-reflux surgery, which mechanically interrupts the reflux of all gastric content including bile.

Treatment Step Four: Anti-Reflux Surgery and Endoscopic Alternatives

When medical therapy fails, when reflux is primarily mechanical from a large hiatus hernia, or when long-term acid suppression is undesirable, anti-reflux surgery becomes a legitimate option. Laparoscopic Nissen fundoplication, the traditional procedure, wraps the fundus of the stomach 360 degrees around the lower oesophagus to restore the antireflux barrier; partial fundoplications such as Toupet (270 degrees posterior) or Dor (180 degrees anterior) trade some reflux control for reduced dysphagia and gas-bloat. The LINX device is a magnetic sphincter augmentation ring placed laparoscopically around the lower oesophagus, offering comparable control of reflux with faster recovery and preserved ability to belch and vomit. Transoral incisionless fundoplication (TIF) and radiofrequency Stretta are endoscopic alternatives for selected patients with smaller hernias and less severe disease. Surgery is most effective when the diagnosis is solid, the patient has objective evidence of reflux on pH-impedance, and the expectations are calibrated: anti-reflux surgery works, but it is a mechanical solution for a mechanical problem, and careful selection is the difference between a happy patient and a disappointed one.

When to See a Specialist

If your reflux persists despite twice-daily PPI, if you have swallowing difficulty, unintentional weight loss, persistent vomiting, or iron deficiency anaemia, if a previous gastroscopy has shown Barrett's oesophagus, if you have been on a PPI for more than five years without reassessment, or if you suspect bile or non-acid reflux because your symptoms feel different from ordinary heartburn, a specialist review is warranted. At Mater Private Hospital in Wollstonecraft, we offer comprehensive assessment of reflux including high-definition gastroscopy with Barrett's mapping and biopsy, 24-hour pH-impedance testing, high-resolution manometry, and reflux scintigraphy where indicated, alongside individualised medical therapy and a close working relationship with upper GI surgeons for patients who are candidates for anti-reflux procedures. Reflux is almost never a trivial condition, and good care matches the treatment precisely to the physiology. If that has not yet happened for you, it is time for the conversation.